ExeVir Bio

This clinical-stage company develops antibody therapies using a modular platform based on camelid antibody fragments (VHH) to treat and prevent infectious diseases. Its pipeline focuses on addressing public health threats such as COVID-19 and dengue, specifically targeting the needs of immunocompromised and vulnerable patients. The technology utilizes multi-specific single domain antibodies designed to bind to conserved epitopes, providing stability and cost-effective production compared to traditional methods.